Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BMS-562086

Latest Information Update: 04 Jun 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antidepressants; Anxiolytics; Pyrazoles; Small molecules
  • Mechanism of Action Corticotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Generalised anxiety disorder; Irritable bowel syndrome; Major depressive disorder

Most Recent Events

  • 22 May 2008 Efficacy data from a phase II trial in irritable bowel syndrome presented at the Digestive Disease Week 2008 (DDW-2008)
  • 15 Jan 2008 Pexacerfont is still in phase II trials for Irritable bowel syndrome in the US
  • 31 Jul 2005 Phase-I/II clinical trials in Depression in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top